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Abstract
Rationale: Previous work found the lung microbiome in healthy
subjects infected with HIV was similar to that in uninfected subjects.
We hypothesized the lung microbiome from subjects infected with
HIV with more advanced disease would differ from that of an
uninfected control population.
Objectives: To measure the lung microbiome in an HIV-infected
population with advanced disease.
Methods: 16s RNA gene sequencing was performed on acellular
bronchoalveolar lavage (BAL)fluid from30 subjects infectedwithHIV
with advanced disease (baseline mean CD4 count, 262 cells/mm3)
before and up to 3 years after starting highly active antiretroviral
therapy (HAART) and compared with 22 uninfected control subjects.
Measurements and Main Results: The lung microbiome in
subjects infected with HIV with advanced disease demonstrated
decreased alpha diversity (richness and diversity) and greater beta
diversity compared with uninfected BAL. Differences improved with
HAART, but still persisted up to 3 years after starting
therapy. Population dispersion in the group infected with HIV
was significantly greater than in the uninfected cohort and
declined after treatment. There were differences in the
relative abundanceof somebacteria between the twogroups at baseline
and after 1 year of therapy. After 1 year on HAART, HIV BAL
contained an increased abundance of Prevotella and Veillonella,
bacteria previously associated with lung inflammation.
Conclusions: The lung microbiome in subjects infected with HIV
with advanced disease is altered compared with an uninfected
population both in diversity and bacterial composition. Differences
remain up to 3 years after starting HAART. We speculate an altered
lung microbiome in HIV infection may contribute to chronic
inflammation and lung complications seen in the HAART era.
Keywords: lung microbiome; HIV infection; advanced disease;
microbial diversity
Recognition of the potential impact of the
human microbiome on health and disease
led the National Institutes of Health to add
the Human Microbiome Project to the
National Institutes of Health Roadmap in
2007. Microbiomes of the gastrointestinal
tract, oral and nasal cavities, skin, and
urogenital tract have now been extensively
characterized in healthy individuals and
in various disease states. Analysis of the
respiratory microbiome was initially
hindered by the belief that the healthy
lung is sterile. However, use of culture-
independent microbial detection methods,
such as 16S ribosomal RNA (rRNA) gene
sequencing, has strongly suggested that a
lung microbiome is present, both in healthy
(1–3) and diseased (1, 4, 5) populations.
In 2009 the Lung HIV Microbiome
Project (LHMP) consortium was formed by
the NHLBI to study the lung microbiome.
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Because pulmonary complications remain
a major cause of morbidity in subjects
infected with HIV even in the highly active
antiretroviral therapy (HAART) era (6), the
fundamental question raised by the LHMP
was whether HIV infection altered the
respiratory microbiome. In a recently
published consortium paper, the primary
finding was that in a large healthy HIV
cohort (median CD4 count in treatment-
naive subjects, 668 cells/mm3; in subjects
on HAART, 618 cells/mm3), the respiratory
microbiome measured in whole
bronchoalveolar lavage (BAL) was
indistinguishable between an HIV-infected
and uninfected population (7). To further
address whether subjects infected with
HIV with more advanced disease had a
respiratory microbiome that differed from
uninfected subjects and to determine the
effect of HAART on the respiratory
microbiome, we took advantage of a cohort
of subjects infected with HIV who were
studied with BAL before and up to 3 years
after starting HAART. We found that
treatment-naive subjects infected with HIV
with lower CD4 counts have a respiratory
microbiome that differs significantly from
uninfected subjects. Furthermore, we show
that HAART induces significant changes in
the respiratory microbiome, although it
remains different from uninfected control
subjects even up to 3 years after starting
therapy.
Methods
Participants
Twenty-two participants uninfected with
HIV were recruited in Indianapolis,
Houston, and Atlanta as part of the LHMP.
The HIV cohort consisted of 30 subjects
who underwent bronchoscopy before
and at 1 month, 1 year, and 3 years
after starting HAART as part of a
prospective trial to assess risk factors for
the immune reconstitution syndrome
(IRIS) in subjects starting HAART. All
subjects with HIV had to have a CD4 count
less than 500 cells/mm3 at baseline. This
research was approved by the Institutional
Review Board at Indiana University, the
University of Arizona, University of
Houston, and Emory University. For
more details on subject characteristics see
the METHODS section in the online
supplement.
Table 1. Baseline Characteristics
HIV (n = 30) Uninfected (n = 22) P Value
Baseline demographics
Age 37.3 (9.2) 47.9 (10.9) 0.0004
Race, n (%)
African American 10 (33.3) 14 (63.6) 0.03
White 20 (66.7) 8 (36.4)
Sex, n (%)
Female 6 (20.0) 5 (22.7) 1.0
Male 24 (80.0) 17 (77.3)
Smoker, n (%)
No 9 (30.0) 14 (63.6) 0.016
Yes 21 (70.0) 8 (36.4)
Duration of HIV, yr
Mean 3.99 N/A
Median 1.75 N/A
Obstructive lung disease, n
COPD 0 N/A
Asthma 2 N/A
Pulmonary HTN, n 0 N/A
Prior PCP infection, n 2 N/A
Prior Kaposi sarcoma, n 2 N/A
BAL yields
BAL fluid, ml 123.16 29.4 118.36 33.0 0.589
Total cells, 106 59.56 33.4 14.06 16.3 0.006
Macrophages, % 84.76 12.3 88.26 11.5 0.31
Lymphocytes, % 13.56 12.2 8.96 9.8 0.16
Neutrophils, % 1.56 3.0 0.86 1.0 0.25
Eosinophils, % 0.36 0.8 0.16 0.3 0.31
Definition of abbreviations: BAL = bronchoalveolar lavage; COPD = chronic obstructive pulmonary
disease; HTN = hypertension; N/A = not applicable; PCP = Pneumocystis carinii pneumonia.
Table 2. Response to HAART in the Population Infected with HIV (Median and Interquartile Range)
Baseline 4 Weeks
Baseline versus
4 Weeks 1 Year
Baseline
versus 1 Year 3 Years
Baseline versus
3 Years
CD4
count
280 (92–385) 311 (189–459) 0.222 400 (236–469) 0.012 375 (318–529) 0.029
Viral load 76,554 (24,100–125,000) 299 (156–1,090) ,0.0001 25 (25–79) ,0.0001 25 (25–407) ,0.0001
Definition of abbreviation: HAART = highly active antiretroviral therapy.
At a Glance Commentary
Scientific Knowledge on the
Subject: A recently published
article demonstrated that the lung
microbiome in healthy subjects
infected with HIV with preserved CD4
counts is similar to that of an
uninfected population.
What This Study Adds to the
Field: In this work we found that
treatment-naive subjects infected with
HIV with more advanced disease have
an altered lung microbiome compared
with uninfected control subjects.
Furthermore, longitudinal data
indicated that the microbiome was
affected by antiretroviral therapy but
still did not return to normal after up to
3 years of treatment.
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BAL Collection and Processing
Bronchoscopy with BAL was performed
as previously described (8). Lavage fluid
was passed through a 100-mm mesh to
remove debris and then centrifuged at
400 3 g for 10 minutes to pellet BAL cells.
The acellular supernatant was harvested
and stored at 2708C for subsequent batch
DNA extraction and 16S rRNA gene
sequencing. In this study we have analyzed
acellular BAL fluid (not whole BAL as
in the consortium paper) because of
our belief that acellular BAL yields a
more distinct respiratory microbiome
(compared with oral washes) than whole
BAL (9).
16S Gene Sequencing
Acellular BAL obtained at other sites was
shipped to Indiana for DNA isolation and
sequencing. Samples from all sites were
processed at the same time. Thus, other
than BAL acquisition variables, all samples
were processed identically. DNA was
extracted from 5 ml of acellular BAL as
previously described (7) and shipped to
The Genome Institute at Washington
University for sequencing using Roche 454
FLX Titanium platform (Branford, CT) as
previously described (2, 4). Primers for
variable regions 1 through 3 (V1–3) were
used. The 16S sequences were processed
with the Mothur package (version 1.29)
(10). High-quality 16S sequences from
each sample were classified using the RDP
Classifier (version 2.5) (11) with the
default cutoff value of 0.8 from phylum to
genus level. Species-level operational
taxonomic units (OTUs) were produced
by Mothur and BLASTed (12) against the
RDP 162 database release 11.4 (13). Top
BLAST hits were used as species-level
annotations if the BLAST alignment
achieved greater than or equal to 95%
coverage and greater than or equal to 98%
sequence identity. The METHODS section in
the online supplement provides more
details on sequencing.
Data Analysis and Statistics
Baseline subject characteristics were
compared using chi-square tests and two-
sample Student’s t tests after logarithmic
transformation if data were skewed. To
account for the uneven sequencing depth
between samples, a normalized procedure
was used as previously described (14, 15).
Differences in the abundance of specific
genera between groups (i.e., uninfected vs.
untreated, uninfected vs. 1-yr treated, and
uninfected vs. 3-yr treated) were analyzed
using negative binomial regression models.
Alpha diversity richness was measured
using Chao 1 and abundance-based
coverage estimators (ACE) indices, and
diversity evenness was assessed using the
Shannon diversity index and Simpson’s
index of diversity (1-D) (16). Alpha
diversity between uninfected and infected
groups was compared using linear
regression models. Alpha diversity between
untreated and treated groups was compared
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Figure 1. Comparison of alpha diversity in acellular bronchoalveolar lavage fluid at the operational
taxonomic unit level between uninfected subjects (black), untreated subjects infected with HIV
(red), and subjects infected with HIV treated with highly active antiretroviral therapy for 1 year
(purple). Richness (A and B) and diversity (C and D) are significantly greater in the uninfected
population compared with a treatment-naive population infected with HIV. However, differences
between the population infected with HIV and uninfected control subjects are less after 1 year of
treatment. ACE = abundance-based coverage estimators.
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using mixed linear regression models
(i.e., subject as random effect) by taking the
correlations among the longitudinal data
from the same subject into consideration.
Beta diversity was visualized using
nonmetric multidimensional scaling (17)
and analyzed by measuring Bray-Curtis
dissimilarity (18, 19) and UniFrac distances
(20, 21). The PERMANOVA test was used
to compare UniFrac distances or Bray-
Curtis dissimilarities (22, 23) between
various populations. Multivariate dispersion
of groups was compared using the betadisper
command in R vegan package (24, 25).
Principal coordinates analysis (26) was
performed at http://unifrac.colorado.edu.
Benjamini-Hochberg corrections were used
to adjust for multiple testing. The METHODS
section in the online supplement provides
statistical details.
Results
Subject Demographics
There were BAL samples from 22 uninfected
control subjects and 30 subjects infected
with HIV (Table 1). Subjects infected with
HIV were significantly younger, more likely
to be white, and had a higher incidence of
smoking than the uninfected control
population. Table 2 shows baseline CD4
counts and viral loads in the HIV-infected
cohort and the changes that occurred on
HAART. All 30 subjects had a minimum
follow-up of 1 year on HAART, and
12 subjects had 3 years of follow-up. HIV
infection was advanced at baseline as
evident by a median CD4 count of
280 cells/mm3 and a median viral load of
76,556 copies/ml. Antiretroviral treatment
was effective as evidenced by a rapid and
sustained drop in viral load and improved
CD4 counts over the course of the study,
although CD4 counts still remained well
below those in the LHMP consortium
paper (7). Importantly, although the HIV
cohort was from a prospective cohort to
identify IRIS in subjects infected with HIV
starting antiretroviral therapy, none of the
subjects had clinically significant IRIS
events at the time of study. Furthermore,
despite the increased incidence of smoking
in the HIV population, spirometry was
normal in this group (see Table E1 in
the online supplement). As a result, no
subject was on inhaled steroids and only
3 of the 30 subjects were on inhaled
albuterol.
Sequencing Yields
Genomic DNA was isolated from 5 ml of
stored acellular BAL. The amount of
genomic DNA isolated from acellular BAL
was similar in the two groups. Genomic
DNA was amplified with V1–V3 primers
and 16S rRNA gene sequencing was
performed. The average numbers of high-
quality sequences were similar in the
different groups, as was the number of
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Figure 2. Comparison of beta diversity in bronchoalveolar lavage at the operational taxonomic
unit level between uninfected subjects and untreated subjects infected with HIV using UniFrac Principal
Coordinate Analysis. (A) The population infected with HIV (red) was significantly different compared with
bronchoalveolar lavage from uninfected subjects (black). P = 0.001 using the PERMANOVA test. (B)
Subdividing subjects infected with HIV into those with CD4 counts higher than (green) or lower than
(blue) 350 cells/mm3 did not affect the results. NMDS= nonmetric multidimensional scaling.
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bacteria identified at the genus level using
the default confidence cutoff of 80% (see
Table E2). After removing samples with less
than 500 reads, there were 20 uninfected
subjects (10 from Indiana, five from Emory,
five from the University of Houston),
26 subjects infected with HIV at baseline,
22 subjects infected with HIV at 1 month of
treatment, 25 subjects infected with HIV at
Year 1 of treatment, and 9 subjects infected
with HIV at Year 3 of treatment.
Baseline Comparison of HIV with
Uninfected BAL Microbiome
16S rRNA gene sequences from acellular
BALs of 20 uninfected and 26 treatment-
naive subjects infected with HIV were
compared. At the OTU level Chao1 and
ACE analysis demonstrated BAL from
uninfected subjects was significantly richer
compared with a treatment-naive HIV
population (Figures 1A and 1B).
Furthermore, Shannon and Simpson alpha
diversity analysis showed that BAL from
the uninfected population was significantly
more diverse compared with BAL from the
subjects with HIV (Figures 1C and 1D).
Differences in alpha diversity indices
remained even after adjusting for age, race,
and smoking status (results not shown).
Nearly identical results were seen when the
same analysis was performed at the genera
level instead of OTUs (see Figure E1).
Next, population beta diversity at the
OTU level was examined using weighted
UniFrac analysis. BAL from subjects
infected with HIV was significantly different
compared with BAL from uninfected
subjects (Figure 2A). These findings held
even when considering the different sites
from which uninfected control subjects
came (see Figure E2). Subdividing the HIV
cohort into subjects with CD4 counts above
and below 350 cells/mm3 (Figure 2B) did
not alter the results, although it should be
emphasized that all of our subjects had
CD4 counts less than 500 cells/mm3 at
baseline. Similar results were obtained
when analyzing population beta diversity
at the genera level using Bray-Curtis
Dissimilarity (see Figure E3). Interestingly,
when dispersion of the two communities
was analyzed, the untreated population
infected with HIV was significantly more
spread out compared with the normal
population (average weighted UniFrac
distance to centroid at the OTU level: 0.167
for the uninfected group, 0.204 for the
untreated HIV-infected group; P = 0.041).
Thus, although BAL microbiome diversity
is low in an individual untreated subject
infected with HIV compared with an
uninfected volunteer, as a group the BAL
microbiome from untreated subjects
infected with HIV is much more varied
than in uninfected subjects, with large
differences between members of the HIV
cohort.
We next investigated whether any
bacterial taxa were different between
uninfected subjects and subjects infected
with HIV using a negative binomial model
shown to be suitable for microbiome data
(27). We limited this analysis to bacteria
that were present in greater than 0.5%
abundance in at least one population.
The top 15 most abundant genera in
uninfected subjects and subjects infected
with HIV are shown in Table E3. After
correction for multiple test comparisons,
seven bacteria genera were found in
different abundance between uninfected
subjects and untreated subjects with HIV
(Table 3). The most notable differences
were an increase in the abundance of
Streptococcus in the HIV population and
an increase in Flavobacterium in the
control population.
Effect of HAART on the HIV BAL
Microbiome
After 1 year of therapy differences in alpha
diversity between uninfected and HIV BAL
persisted, although in most instances the
difference declined (Figure 1). Differences
in beta diversity between uninfected BAL
and BAL from treated subjects infected
with HIV also persisted after 1 year on
therapy (Figure 3 shows OTU level; Figure
E4 shows genera level). However, UniFrac
distances between uninfected subjects and
subjects infected with HIV treated for
1 year were significantly less than distances
between uninfected subjects and untreated
subjects infected with HIV (P = 0.012)
(see Figure E5), suggesting after 1 year of
treatment HIV BAL contained more taxa
similar to uninfected control subjects.
Furthermore, principal coordinates analysis
using weighted and normalized UniFrac
distance showed beta diversity within the
population infected with HIV decreased
with time on HAART (Figures 4A–4D),
suggesting the population was becoming
more uniform over time. This was
confirmed by dispersion analysis using
weighted UniFrac distance (Figure 4E),
showing that the population spread in
subjects infected with HIV after 1 year of
HAART was significantly less than in the
untreated population (average distance to
centroid: 0.157 for the 1-yr treated group,
0.204 for the untreated group; P = 0.005)
and was no longer significantly different
from uninfected control subjects (average
distance to centroid: 0.167 for the
uninfected group, 0.157 for the 1-yr treated
group; P = 0.48). Results were nearly
identical if analysis was confined to only those
subjects who had both baseline and 1-year
data available for comparison (P = 0.01).
These data suggest BAL differences in alpha
and beta diversity between uninfected
subjects and subjects infected with HIV
decrease with antiretroviral treatment, but
have not returned to normal after 1 year of
therapy.
Next, we investigated which specific
bacterial taxa might be different between
uninfected subjects and subjects with HIV
after 1 year of treatment (Table 4). The top
15 most abundant genera after 1 year
of treatment are shown in Table E3.
Streptococcus remained more abundant in
the HIV population and Flavobacterium
remained more abundant in the control
population. Interestingly, after 1 year of
Table 3. Most Significant Differences between Uninfected Subjects and Subjects
Infected with HIV at Baseline
Organism
Uninfected (%) HIV (%)
P ValueMean SD Mean SD
Streptococcus 11.9 10.44 27.9 24.64 0.017
Flavobacterium 13.2 10.86 0.008 0.04 ,0.00001
Curvibacter 0.6 0.54 0 0 0.0004
Methylobacterium 0.7 1.24 0.1 0.44 0.04
Corynebacterium 1.9 1.86 0.4 1.12 0.04
Rickettsia 0.6 0.72 0 0 0.002
Borrelia 0.6 1.02 0 0 0.004
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HAART BAL from the HIV group now
contained a greater amount of Veillonella
and Prevotella compared with uninfected
BAL. By 3 years after starting HAART the
differences in the abundance of
Streptococcus and Flavobacterium were
much less compared with previous time
points (P = 0.03 for Streptococcus and P =
0.04 for Flavobacterium). Furthermore, at
this time point differences in abundance of
Veillonella and Prevotella were no longer
statistically different between the two
groups. However, 3-year data should be
viewed cautiously because they are based on
only nine subjects infected with HIV from
the original cohort.
Finally, given the potential importance
of Veillonella and Prevotella as components
of a proinflammatory lung microbiome
(28), we specifically assessed changes in
these organisms over time in the population
infected with HIV. Table 5 shows that
the relative abundance of these genera
increased between baseline and 1-year
treated subjects. By 3 years of treatment the
abundance of Prevotella had significantly
decreased, whereas the abundance of
Veillonella remained stable.
Discussion
We have demonstrated that untreated
subjects infected with HIV with advanced
disease have an altered respiratory
microbiome measured in acellular BAL
characterized by decreased alpha diversity
(less richness and diversity) and greater beta
diversity compared with normal BAL. These
differences improve with time on HAART,
but still have not returned to normal up to
3 years after starting therapy, at a time when
the peripheral blood CD4 count has
improved but is still significantly below
normal. Population dispersion in the
untreated group infected with HIV is
significantly greater than in the uninfected
cohort, but declines with treatment. We
further identify differences in relative
bacterial abundances in HIV-infected BAL
compared with uninfected BAL both in
untreated subjects and those who have been
on HAART for 1 year. Finally, after 1 year
on HAART, HIV BAL contains an increased
abundance of Prevotella and Veillonella,
bacteria previously associated with lung
inflammation (28).
These results differ from a recent
LHMP consortium paper demonstrating
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Figure 3. Comparison of beta diversity in bronchoalveolar lavage at the operational taxonomic
unit level between uninfected subjects and treated subjects infected with HIV using weighted
UniFrac Distance visualized by NMDS. Subjects infected with HIV who have been treated for 1 year
(A), and for 3 years (B). The population infected with HIV (red) remains significantly different
compared with bronchoalveolar lavage from uninfected subjects (black) even after 1 year on
therapy. This difference is slightly less after 3 years of highly active antiretroviral therapy.
NMDS = nonmetric multidimensional scaling.
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that the lung microbiome measured in
whole BAL was indistinguishable between a
healthy population infected with HIV and
uninfected control subjects (7). This finding
was unexpected given the high incidence
of pulmonary complications in this
population. Our results demonstrate that
subjects infected with HIV with more
advanced disease have a significantly
different respiratory microbiome when
compared with uninfected subjects and that
differences decrease with time on HAART.
Taken together, these two reports suggest
that in healthy subjects infected with HIV,
even those who have low CD4 counts
before starting antiretroviral therapy, it is
possible to attain a more normal-appearing
lung microbiome as assessed by various
diversity indices and the presence of
signature bacteria. Our findings and those
of the consortium further support the
evolving practice of starting patients
infected with HIV on antiretroviral therapy
at earlier time points to try and prevent
more severe immunologic and
inflammatory perturbations and limit HIV-
related complications (29, 30).
Our cohort also differs significantly
from the work of Iwai and colleagues (31),
who examined the lung microbioime in a
Ugandan cohort of subjects infected with
HIV with pneumonia. Despite differences
in the cohorts, some interesting similar
results were seen. First, Prevotella was one
of the shared taxa identified in the entire
Ugandan population, and Prevotella was
the most significant contributor to the
bacteria found in our patients infected with
HIV after 1 year of HAART. Second, both
the Ugandan and U.S. cohort demonstrated
a large amount of beta diversity within the
population suggesting it was not unusual
for different specific bacteria to dominate
the lung microbiome in individual subjects
infected with HIV. In fact, we speculate that
the large beta diversity in an untreated
population infected with HIV makes
comparisons of specific bacterial
abundances between this group and an
uninfected population problematic. This
could explain why after 1 year of treatment,
at a time when beta diversity has declined
and the population infected with HIV has
become more uniform, greater number of
different bacterial abundances are now
found between the HIV-infected and
uninfected population comparison.
The presence of Prevotella and
Veillonella as dominant organisms in
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Figure 4. (A–D) UniFrac principal coordinates analysis of bronchoalveolar lavage samples from
subjects infected with HIV before treatment and at 4 weeks, 1 year, and 3 years after therapy.
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subjects infected with HIV after 1 year of
HAART is intriguing in light of recent work
by Segal and colleagues (28) demonstrating
that the presence of these organisms defines
a microbiome pneumotypeSCT believed
to be most reflective of a true lung
microbiome from chronic microaspiration.
Furthermore, these investigators demonstrate
this pneumotype is associated with markers
of lung inflammation. Numerous studies
have demonstrated persistence of chronic
lung inflammation even in subjects infected
with HIV on HAART (32–34). It is tempting
to speculate that this chronic inflammation
may contribute to lung complications seen
in the HAART era, which have moved away
from classic opportunistic infections
toward more chronic lung diseases, such as
chronic obstructive pulmonary disease,
pulmonary hypertension, and lung cancer
(35). It is important to determine if similar
correlations between the lung microbiome
and markers of inflammation exist in these
cohorts.
The other major difference between the
two groups was an increased abundance of
Streptococcus and a lower abundance of
Flavobacterium in the HIV-infected group
compared with uninfected subjects both
at baseline and after 1 year of HAART.
Interestingly, by 3 years after starting
HAART all these differences (including the
abundance of Prevotella and Veillonella)
were less pronounced or had resolved.
Although these results should be viewed
with caution because of smaller sample size,
they do indicate the possibility that
antiretroviral therapy can return the lung
microbiome to a more normal-appearing
phenotype.
A key feature of our analysis is that
it was performed on acellular BAL. The
literature is mixed with some reports using
acellular BAL (28), whereas others use
whole BAL (2). Dickson and colleagues (36)
have shown that analysis of whole and
acellular BAL microbiomes yields different
results. We also found that analysis of
acellular and whole BAL yields different
results (9). Furthermore, we found that
acellular BAL is more distinct from oral
wash (the presumed major source of upper
airway contamination when obtaining BAL
using bronchoscopic techniqes) compared
with whole BAL, which we speculate is
because of the pulling down of larger upper
airway biofilms and bacterial clumps during
the cell separation process (9). Because
analysis of acellular BAL contains fewer
bacteria shared with the upper airway, it
may more closely represent true unique
lung organisms. However, the loss of
potential cell-associated bacteria during this
process is an important consideration when
viewing our results in the context of other
published data.
Our study has several strengths and
weaknesses. The greatest strengths of this
work are the longitudinal nature of the
data and that we studied subjects infected
with HIV with more advanced disease
but who were otherwise healthy at the
time of bronchoscopy. Our cohort was
also large enough to examine confounders
between the uninfected and HIV-
infected population, including age, race,
and smoking differences. Finally, all
samples were processed at the same time
in the same place, minimizing the
potential of confounding batch effects
despite getting samples from different
sites.
Despite this, a weakness in our study is
the lack of upper airway and environmental
controls in the longitudinal HIV-infected
cohort. The importance of upper airway and
environmental controls when trying
to define a unique lower respiratory
microbiome has been emphasized (37).
Because the HIV-infected cohort came
from a prior prospective study,
environmental and upper airway controls
were not available. Nevertheless, the
longitudinal nature of this cohort strongly
suggests that the changes observed over
time are significant. Furthermore, our
uninfected volunteer population did have
oral wash and environmental controls. As
previously described (4), we saw clear
separation between BAL and oral wash
samples in the uninfected population (see
Figure E6). Furthermore, environmental
controls demonstrated that preprocedure
bronchoscopic washes, an appropriate
control for environmental contamination
(37), were completely different from lung
and oral specimens (see Figure E6). Finally,
we had fewer subjects who participated in
research BAL at 3 years after initiation of
HAART, limiting conclusions that can be
drawn at this time point.
In summary, we have compared the
microbiome in acellular BAL fluid from
a population infected with HIV with
advanced disease before HAART and an
uninfected control population, and
differences over time with initiation of
Figure 4. (Continued). With time on therapy, the subjects infected with HIV demonstrate more clustering, indicating a decrease in beta diversity within the
population. (E) Principal coordinates analysis scatter plot of baseline and 1 year after treatment groups using weighted UniFrac distances. Multivariate
homogeneity of group dispersions analysis showed dispersion of the population infected with HIV after 1 year of therapy was significantly less than in the
untreated population (P = 0.005). PC = principal coordinate.
Table 4. Most Significant Differences between Uninfected Subjects and Subjects
Infected with HIV after 1 Year of Treatment
Organism
Uninfected (%) HIV (%)
P ValueMean SD Mean SD
Streptococcus 11.9 10.50 21.6 14.66 0.02
Flavobacterium 13.2 10.86 0 0 ,0.00001
Prevotella 9.8 8.40 21.9 9.38 0.001
Veillonella 3.9 3.88 8.1 5.84 0.02
Corynebacterium 1.9 1.86 0.2 0.80 0.001
Curvibacter 0.6 0.54 0 0 0.0001
Methylobacterium 0.7 1.24 0 0 0.0001
Staphylococcus 2.0 4.40 0.04 0.16 0.0008
Rickettsia 0.6 0.71 0 0 0.002
Borrelia 0.6 1.03 0 0 0.001
Actinomyces 2.0 2.24 7.9 6.08 ,0.00001
Burkholderia 0.5 0.64 0.02 0.08 0.0001
Propionibacterium 1.0 1.18 0.2 0.42 0.001
Sneathia 0.11 1.65 1.1 1.68 0.003
Atopobium 0.4 0.54 0.9 0.68 0.01
Parvimonas 0.5 0.64 1.1 1.0 0.02
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HAART. In contrast to subjects infected
with HIV with preserved CD4 counts, those
with lower CD4 cell counts have an altered
alveolar microbiome characterized by a loss
of richness and diversity within individuals,
but an increase in differences between
subjects. These differences decrease with
time on HAART, but have not returned to
normal up to 3 years after starting
treatment, when CD4 counts have improved
but still remain lower than normal.
Finally, the alveolar microbiome in subjects
infected with HIV contain increased
amounts of some signature bacteria even
after 1 year of HAART, some of which have
been previously associated with chronic
lung inflammation. Future studies need to
link lung microbiome alterations in HIV
infection with pulmonary immunologic
and inflammatory perturbations as
potential mechanisms to explain the
changing spectrum of pulmonary
complications in patients living with
HIV. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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